A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
- Sponsor:
- Gilead Sciences, Inc.
- Sponsor Study ID:
- ASCENT-05 / GS-US-595-6184
- CTO #:
- 103898
- NCT Number:
- NCT05633654
- Phase:
- III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Breast
- Study Objectives:
- To compare invasive disease-free survival (iDFS) between SG and pembrolizumab versus treatment of physician s choice (TPC)
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Brescia, Frank, at bresciaf@musc.edu .
- Study Coordinator, Gelardi, Theresa, at gelardi@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina